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Abstract 
In human T-lymphotropic virus type 1 (HTLV-1) infection, a high frequency of HTLV-1-
specific CTLs can co-exist stably with a high proviral load and the proviral load is strongly 
correlated with the risk of HTLV-1-associated inflammatory diseases. These observations led 
to the hypothesis that HTLV-1 specific CTLs are ineffective in controlling HTLV-1 replication 
but contribute to the pathogenesis of the inflammatory diseases.  But evidence from host and 
viral immunogenetics and gene expression microarrays suggests that a strong CTL response is 
associated with a low proviral load and a low risk of HAM/TSP.   Here, we quantified the 
frequency, lytic activity and functional avidity of HTLV-1-specific CD8+ cells in fresh, 
unstimulated PBMCs from individuals with natural HTLV-1 infection.  The lytic efficiency of 
the CD8+ T-cell response – the fraction of autologous HTLV-1-expressing cells eliminated per 
CD8+ cell per day – was inversely correlated with both the proviral load and the rate of 
spontaneous proviral expression.   The functional avidity of HTLV-1-specific CD8+ cells was 
strongly correlated with their lytic efficiency.  We conclude that efficient control of HTLV-1 in 
vivo depends on the CTL lytic efficiency, which depends in turn on CTL avidity of antigen 
recognition.  CTL ‘quality’ determines the position of virus-host equilibrium in persistent 
HTLV-1 infection. 
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Introduction 
 
The retrovirus human T-lymphotropic virus type 1 (HTLV-1) causes two distinct types of 
disease: a malignancy of CD4+ T cells known as adult T-cell leukaemia/lymphoma (ATLL) 
and a range of inflammatory diseases, of which HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) is the best recognized and most widely studied.  Over 90% of 
HTLV-1-infected individuals develop no associated disease.  The reasons why the minority 
develop these conditions are not yet identified.  A high proviral load of HTLV-1, i.e. a high 
frequency of provirus-carrying cells in the circulation, is associated with a high risk of 
developing HTLV-1-associated diseases (1); however, the factors that determine an 
individual’s proviral load of HTLV-1 are poorly defined. 
 
HTLV-1 infection elicits a strong cytotoxic T lymphocyte (CTL) response (2).  The frequency 
of HTLV-1-specific CTLs is often very high: 1 to 10% of circulating CD8+ T cells can 
recognize a single epitope in the immunodominant CTL target antigen, Tax protein (3).  
Furthermore, the frequency of specific CTLs may be positively correlated with the proviral 
load of HTLV-1 (4), and can be particularly high in patients with HAM/TSP (5). These 
observations gave rise to the suggestion that HTLV-1-specific CTLs not only fail to eradicate 
the virus but may in fact cause the inflammatory tissue damage seen in HAM/TSP (6).  
However, there is also evidence from a number of experimental approaches that the CTL 
response to HTLV-1 is a major determinant of the control of the proviral load and is thus 
important in the protection against HTLV-1-associated diseases such as HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP).  An immunogenetic study showed a 
strong association between a lower risk of developing HAM/TSP and a particular MHC class I 
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genotype in a group of HTLV-1 patients in Japan (3). Using DNA expression microarrays it 
was found that genes that encode cytotoxicity effector proteins are expressed at a higher level 
in CD8+ cells of patients with low proviral load than in those with high proviral load (7).   
Finally, Tax protein, the immunodominant antigen recognized by HTLV-1-specific CTLs (8) 
(9) (10) is subject to positive selection in vivo (11) (12) (13); the only plausible selection force 
that has been suggested is immune selection exerted by the strong HTLV-1-specific CTL 
response. 
 
We have hypothesized that the steady-state magnitude of the HTLV-1 proviral load, which is 
strongly correlated with the risk of HAM/TSP (1), is determined by the balance between the 
survival and proliferation of infected cells and clearance of productively infected cells by the 
abundant virus-specific CTLs (14) (15).  Further, we propose that a critical factor that 
determines the outcome of HTLV-1 infection is the ‘efficiency’ of the HTLV-1-specific CTL 
response (14, 15).  
 
We have therefore investigated methods of quantifying antiviral CTL ‘efficiency’.  In HTLV-1 
infection, both effector CTLs and infected target cells are often present in fresh blood at 
frequencies sufficiently high to obviate the need for enrichment of specific subpopulations.  
We have exploited this feature to develop an assay of CD8+ cell-mediated suppression of 
HTLV-1 expression in fresh PBMCs (16).  As a marker of proviral expression we use the viral 
protein Tax, a regulatory protein expressed early in the life cycle of HTLV-1 (16). We 
previously showed that this suppression of HTLV-1 depended on CD8+ T cell frequency and 
required both perforin and a match in class 1 MHC genotype between effector and target cells 
(17), consistent with classical class 1 MHC-restricted CTL lysis.   Mathematical modelling can 
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be used to quantify the rate of killing of Tax-expressing CD4+ cells per CD8+ cell per day.  We 
use the term ‘lytic efficiency’ to denote this per-CD8+-cell rate of lysis.  This assay of lytic 
efficiency showed that the rate of CTL-mediated lysis of HTLV-1-infected cells in fresh 
PBMCs was inversely correlated with the proviral load, both in patients with HAM/TSP and in 
asymptomatic HTLV-1 carriers (ACs) (16).  
 
This measure of lytic efficiency has two chief limitations.  First, the antiviral activity is 
expressed per CD8+ cell, not per virus-specific CD8+ cell, since there is no currently available 
method to measure in the same assay the lytic activity and the total frequency of CD8+ T cells 
specific to all viral epitopes in each individual.  Second, rate of lysis is likely to be a composite 
parameter that is a function of both the frequency of the antigen-specific CD8+ cells and the 
“quality” of their effector functions at the single-cell level (18).  In an acute viral infection, 
efficient elimination of the virus is associated with a high frequency of antigen-specific T cells 
(19).  But in persistent infections, the complexity of the equilibrium dynamics makes it 
impossible to infer the efficiency of virus-specific CTLs directly from their steady-state 
frequency (20).   
 
In the present study, we used the sensitivity of viral peptide recognition in an IFN-γ ELISpot 
assay as a measure of the ‘quality’ of the HTLV-1-specific CD8+ response.   This measure is 
often called the ‘functional avidity’ of the T cell; for brevity, we refer to it here as ‘avidity’(21) 
(22).  The aim of the present study was to test the hypothesis that specific CD8+ T cell avidity 
determines the lytic efficiency of HTLV-1-specific CTLs and thereby determines the 
individual’s proviral load.   
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Materials and Methods 
 
PBMC separation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density 
gradient centrifugation using Histopaque-1077 (Sigma, Poole, United Kingdom) from EDTA-
anticoagulated blood samples taken from HTLV-1 infected individuals. All individuals 
attended the HTLV-1 clinic at St Mary’s Hospital, London and gave written informed consent, 
and the study was approved by the St Mary's NHS Trust Local Research Ethics Committee. 
Isolated PBMCs were washed twice in PBS then cryopreserved in fetal calf serum (FCS, 
Sigma) with 10% dimethyl sulfoxide (DMSO, Sigma). 
 
Cell culture 
Cells were thawed, washed twice in PBS and then cultured in complete medium consisting of 
RPMI-1640 medium (Sigma) supplemented with 10% FCS, 2 mM L-Glutamine, 100 U/ml 
Penicillin and 100μg/ml Streptomycin (Gibco). Cells were incubated for different times at 
37oC in 5% CO2. When required, CD8+ or CD4+ cells were depleted by positive selection using 
antibody coated magnetic microbeads following the manufacturer’s instructions (Miltenyi 
Biotec, Surrey, United Kingdom). 
 
ELISpot assay 
To stimulate IFN-γ+ HTLV-1 Tax-specific CD8+ T cells we used two pools of overlapping 20 
mer peptides (offset by 6 amino acids) spanning the full length of the Tax protein, as 
previously described (8).  The use of 20mer peptides, rather than peptides closer in length to 
the typical physiological optimum of ~9 amino acids may reduce the sensitivity of detection of 
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antigen-specific CD8+ T cells.  However, the difference between the response to13mers and 
20mers was not statistically significant (8).  Eighty to one hundred thousand CD4-depleted 
PBMCs were incubated at 37oC  for 6 hours in the presence a range of concentrations (0, 0.01, 
0.1, 1, 5 and 10 M) of the Tax peptide pools in duplicate wells. IFN-γ production by Tax-
specific CTLs was quantified by ELISpot (Mabtech) according to the manufacturer’s 
instructions.  Spot-forming cells (SFCs) were counted using an automated ELISpot reader 
(AID Autoimmun Diagnostika GmbH).  For each peptide pool concentration, the frequency of 
IFN-γ+Tax-specific CTLs was calculated as follows: 
(SFCpoolA+ SFCpoolB – 2* SFCno peptide)/(Total number of CD8+ T cells) 
 
Log10[peptide] was then plotted against the number of IFN-γ+ Tax-specific CTLs.  Using 
Graphpad Prism software, the following equation was fitted to the data: 
    y    =   (Max)/(1+10((LogEC50-x)*Hillslope)) 
 
where x = log10 (peptide concentration); y = % CD8+ cells producing IFN-γ at a given peptide 
concentration; Hillslope = gradient of fitted curve; and Max = predicted maximum SFC (i.e. 
where peptide concentration is not a limiting factor in IFN-γ production by antigen specific 
cells).  The effective concentration of peptide that induced IFN-γ production by half the 
maximum number of Tax-specific cells (EC50) was estimated using this equation, and CD8+ T 
cell avidity was defined as the reciprocal of this value (1/EC50).  Avidity is expressed in units 
of  106M-1. 
 
Flow cytometric detection of Tax expression 
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After incubation, cells were surface-stained with monoclonal antibodies specific to CD4 and 
CD8 at 15 μg/mL in each case (Beckman Coulter, Marseille, France). Cells were fixed with 2% 
paraformaldehyde (PFA, Sigma) and then permeabilized using PBS/0.1% Triton X-100 
(Sigma). Finally, cells were stained intracellularly with the FITC conjugated antibody anti-Tax 
protein Lt-4 (41), diluted 1/100.  Cells were analyzed on a Coulter Epics XL flow cytometer. 
Thirty thousand events were routinely collected during acquisition of the data. The data were 
analysed using Coulter Expo32 software (Beckman Coulter). 
 
Proviral load 
DNA was extracted from 2 x 106 PBMCs as described in the manufacturer’s protocol (Qiagen, 
DNeasy Tissue Kit) and eluted in 100 μl polymerase chain reaction- (PCR-) grade H2O. Eluted 
DNA was amplified for HTLV-1 DNA using the Tax sequence-specific primers previously 
reported (42) and for β-actin (to quantify genomic DNA). DNA was amplified by real time 
quantitative PCR (qPCR) in a Roche light cycler using SYBR® Green 1 Dye incorporation 
(Roche) and 1 μM of each primer. Standard curves were generated using the rat cell line Tarl2, 
which contains 1 copy per cell of the HTLV-1 provirus (1). The sample copy number was 
estimated by interpolation from the standard curve and expressed as percentage of PBMCs 
infected, assuming one proviral copy per cell. 
 
Statistical analysis 
 Spearman’s rank-order test was used to test for correlation between 2 parameters across all 
HTLV-1–infected individuals. The Mann-Whitney test was used to compare the percentage of 
Taxhigh and Taxlow expressing cells between samples or within the same sample. All tests were 
2-tailed and rejected or accepted at the 95 % level. Multiple linear regression analysis was 
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carried out using SPSS (v16.0), with the rate of lysis as the dependent variable and frequency 
and avidity as the predictors.  Raw, log-transformed and ranked data for each predictor were 
analysed.   
 
 
Rate of CD8+ cell-mediated lysis  
The rate (“efficiency”) of CD8+ cell-mediated lysis of HTLV-1-infected cells was estimated as 
previously described (16). CD8+ cell lytic efficiency (expressed as the proportion of Tax-
expressing CD4+ cells killed per CD8+ cell per day) was calculated using the following 
equation: 
 
where y is the proportion of CD4+ cells expressing Tax, c is the rate of increase of Tax 
expression which is assumed to be constant during the short-term culture, ε (epsilon) is the 
CD8+ cell-mediated lytic efficiency and z is the proportion of PBMCs that are CD8+. This 
model was solved analytically and fitted to the data using non-linear least-squares regression 
(SPSS v16),  providing an estimate of the lytic efficiency in each individual. 
 
Rate of CD8+ cell mediated lysis of high Tax and low Tax expressing CD4+ T cells 
We wished to extend the above model to estimate the rate of lysis of high Tax-expressing 
(Taxhigh) and low Tax-expressing (Taxlow) cells. Tax+ cells were divided in flow-cytometric 
analysis into two gates, corresponding respectively to Taxlow and Taxhigh cells according to 
fluorescence intensity.  The line dividing these gates was arbitrarily defined; the same 
definition was used in the analysis of all samples.  Since we observed a continuous increase in 
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the number of cells expressing a high level of Tax during the 18hr incubation (TK and CRMB, 
unpublished observations), we modified the existing model as follows: 
 
 
 
In this model the Taxlow population (as defined from the gated FACS) is produced at a constant 
rate c1 and the Taxhigh population at a rate c2. 
The following pair of linked ordinary differential equations describes the model: 
 
 
Here, y is the proportion of Taxlow CD4+ cells and w is the proportion of Taxhigh CD4+ cells. 
Solving these equations, we have: 
 
 
Equations 4 and 5 were fitted to the data in the absence of CD8+ cells using non-linear least-
squares regression, providing an estimate of c1 and c2 for each individual.   Equations 2 and 3 
were then modified to describe the rate of CD8+ cell-mediated lysis of Taxlow cells and Taxhigh 
cells separately: 
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These equations (Model 2) were solved analytically and fitted to the data using non-linear 
least-squares regression, to produce estimates of the rate of lysis of Taxlow and Taxhigh cells for 
each individual. 
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Results 
 
Control of HTLV-1 expression by CTLs 
Progressive addition of CD8+ cells to freshly isolated, unstimulated PBMCs resulted in a 
progressive decrease in the survival of Tax+CD4+ cells at 18h. Representative data from a 
single patient are shown in Figure 1A. Since this suppression of HTLV-1-expressing cells is 
proportional to CD8+ cell frequency and requires both perforin and a Class 1 MHC match 
between CD4+ (target) and CD8+ (effector) cells (17) we conclude that the suppression 
represents classical, class 1-restricted CTL-mediated lysis of HTLV-1-infected cells.  The rate 
of this CD8+ cell-mediated lysis can be quantified, as previously described (16).  Confirming 
and extending the previous results (16), there was a significant inverse correlation between the 
lytic efficiency and both the proviral load (p<0.05; Spearman rank test, n=16) and the 
frequency of spontaneous Tax protein by freshly isolated, naturally-infected CD4+ T cells after 
overnight incubation (Figure 1B  p<0.05; Spearman rank test, n=16).  These observations 
suggest that an efficient CD8+ cell-mediated response to HTLV-1 (high rate of lysis) reduced 
the proviral load by efficient killing of HTLV-1 infected T cells in vivo.  
 
The efficiency of HTLV-1 suppression depends on the frequency and the avidity of HTLV-1-
specific CD8+ cells  
 
To quantify the contribution of CD8+ T cell avidity to the rate of CD8+ cell-mediated lysis, we 
performed ELISpot experiments using samples of fresh unstimulated PBMCs from HTLV-1-
infected patients. Tax is the immunodominant antigen recognized by HTLV-1-specific CD8+ 
cells (8) (9) (10).  We used a pool of overlapping synthetic peptides from the Tax sequence to 
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stimulate HTLV-1 Tax-specific cells in an IFN-γ ELISpot assay.  We measured the frequency 
and avidity of responding Tax-specific CD8+ cells by performing the ELISpots with a gradient 
of Tax peptide concentrations. Figure 2A shows a representative result for two patients, with or 
without stimulation by Tax peptides. Figure 2B shows an example of the calculation of CD8+ 
cell avidity. The results show a significant positive correlation between the rate of lysis and the 
frequency of the IFN-γ+ Tax-specific CD8+ cells (Figure 3A p<0.05;  Spearman rank test, 
n=16) and between the rate of lysis and the CD8+ cell avidity of recognition of Tax peptides 
(Figure 3B p=0.0017; Spearman rank test, n=15).  The frequency of the CD8+ cells and the 
avidity were also positively correlated (p<0.05; Spearman rank test, n=19).  
 
We then wished to quantify the respective contributions of the avidity and the frequency of 
Tax-specific CTLs to the CD8+ lytic efficiency.  We performed multiple linear regression, with 
the rate of lysis parameter as the dependent variable and frequency and avidity as the 
predictors. This analysis showed that CD8+ T-cell avidity remained a significant predictor of 
lytic efficiency even after the specific CD8+ T-cell frequency was taken into account 
(p=0.0005), whereas frequency lost significance (p=0.85).  To test the robustness of this result, 
we repeated the analysis using transformed data, taking logarithms of the data and taking ranks 
of the data.  In each case, the conclusion remained the same; avidity remained a significant 
predictor of lytic efficiency, while frequency lost significance. We conclude that avidity is a 
significant independent predictor of the quality of the CTL response. 
   
There was a significant inverse correlation (Figure 4 p=0.0039; Spearman rank test, n=19) 
between CD8+ T-cell avidity and the frequency of spontaneous HTLV-1 Tax protein 
expression in PBMCs after overnight incubation in vitro.  This observation suggests that CD8+ 
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T cells from an individual with an “inefficient” CD8+ T cell response to HTLV-1 (low avidity; 
low lytic efficiency) require a significantly greater antigen concentration to elicit an effector T 
cell response.  If true, this implies that HTLV-1-infected CD4+ T cells that express high levels 
of HTLV-1 antigen will be eliminated significantly more rapidly than those that express low 
antigen levels.  To test this hypothesis directly we modified our existing assay of HTLV-1-
specific CD8+ T cell activity in samples of fresh PBMCs from infected individuals.   
 
Taxhigh  cells were killed more rapidly than Taxlow cells by CTLs 
Flow cytometric analysis was used to divide the Tax-expressing population into high Tax-
expressing and low Tax-expressing cells.  Figure 5A shows a representative example of the 
distributions of Tax staining intensity corresponding respectively to the lowest frequency 
(‘depleted’, left panel) and the highest frequency (‘enriched’, right panel) of CD8+ cells used in 
the CD8+ cell lytic efficiency assay.  In all samples tested, enrichment of CD8+ cells was 
associated with a significant decrease in the mean fluorescence intensity of Tax staining 
(p<0.01; Mann-Whitney test, n=22).  
 
We then examined the correlation between the Tax staining intensity and the rate of lysis over 
a number of patients. There was a significant inverse correlation between the lytic efficiency 
and the percentage of cells present in the Taxhigh gate (Figure 5B; p<0.05; Spearman rank test, 
n=17,).  
 
Time-course analysis revealed a progressive increase in both the frequency and intensity of 
Tax staining during 18 hours’ incubation in vitro (TK and CRMB, unpublished observations).  
That is, there was a progressive movement of Tax+ cells from the Taxlow gate to the Taxhigh 
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gate, and these two populations cannot be considered to be independent of each other.  The 
lysis rate equation (equation 1, Material and Methods section) was therefore modified to take 
into account this continuous increase in Tax expression.  To quantify the rates of lysis of 
Taxhigh and Taxlow cells respectively, the modified lysis rate equations (equations 6 and 7) were 
then solved and fitted to the experimental data.  The results (Figure 5C) show a statistically 
significantly higher rate of CD8+ cell-mediated lysis of the Taxhigh cells than that of the Taxlow 
cells (p<0.01; Mann-Whitney test; n=14).   
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Discussion 
 
In the present study we quantified the contributions of CD8+ T-cell quality and frequency to 
the efficiency of the specific CTL response in natural HTLV-1 infection in humans.  As a 
measure of CTL quality, we quantified the concentration of viral peptides required to elicit a 
half-maximal response in a CD8+ IFN- ELISpot assay.  We refer to the reciprocal of this 
measure as CTL avidity.  The major conclusions are that the efficiency of the CTL response 
correlates with the avidity of CTL recognition of viral antigen, and that this CTL efficiency 
correlates with the proviral load, which is in turn the strongest correlate of disease in HTLV-1 
infection.  
 
HTLV-1 infection is characterized by a strong cell-mediated immune response:  the frequency 
of HTLV-1-specific CTLs is particularly high (4, 5).  The proviral load, i.e. the fraction of 
PBMCs that carry a provirus, varies more than 1000-fold among infected individuals, and can 
exceed 20% of PBMCs (1).  The high frequency of HTLV-1-specific CTLs, especially in 
individuals with HAM/TSP, has led to the suggestion that these cells fail to control HTLV-1 
replication, and indeed that they may contribute to the inflammatory tissue damage seen in 
HAM/TSP and related inflammatory diseases (6) (23) (24) (25).  However, we have argued 
from both experimental evidence (4) (26) and theoretical considerations (27) that the complex 
dynamics of the equilibrium between a host immune response and a persistently replicating 
pathogen makes the equilibrium frequency of the pathogen-specific CTLs an unreliable guide 
to their efficacy. The correlation between HTLV-1-specific CD8+ cell frequency and HTLV-1 
proviral load is either zero (26) or weakly positive (4, 5) (26). A similar problem is evident in 
HIV infection, in which there may be simultaneously both significant positive and significant 
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negative correlations between plasma viral load and the frequency of CTLs specific to different 
respective epitopes in the same patient cohort  (28) (29).  Recent studies of CTLs specific for 
single epitopes of HIV-1 suggested a correlation between CTL functional avidity and efficient 
control of the viral load (30) (31) and T-cell “quality” rather than “quantity” determines viral 
dynamics (32).  The present results demonstrate that this correlation holds, in HTLV-1 
infection, across all epitopes in the immunodominant antigen of HTLV-1 in functional assays 
of fresh, unstimulated peripheral blood T cells.  
 
CD8+ T cells have been shown in vitro to require only 10 complexes of MHC/peptide to elicit a 
lytic effector response (33) (34) (35).  The detection of a significant difference in the rate of 
CTL-mediated lysis between cells with high Tax expression and those with low Tax expression 
was therefore surprising, since even the ‘low’-Tax cells contain sufficient Tax protein to be 
readily detected by flow cytometry.  Inefficient lysis might be caused by inefficient antigen 
processing, which would result in turn in few MHC/Tax peptide complexes being presented on 
the infected cell surface, despite the high level of intracellular Tax protein as indicated by 
intracellular staining.  Alternatively, it is possible that there is not a uniformly high probability 
of CTL-mediated lysis when a low threshold of MHC/peptide density on the cell surface is 
exceeded, but rather that the probability of CTL-mediated lysis increases progressively with 
increasing density of MHC peptide complexes.  Finally, it is possible that despite the 
immunogenicity of Tax protein in the CD8+ T cell response (8), recognition of another HTLV-
1 antigen by CTLs might be the factor that limits the rate of HTLV-1 replication in vivo (5) 
(36).   
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The conclusion that the immune control of HTLV-1 depends on the efficiency or ‘quality’ of 
virus-specific CD8+ T cells is consistent both with previous theoretical analysis (27) (26) (20) 
and with recent experimental observations by Sabouri et al (37). These authors used CD107 
LAMP-1) staining of CD8+ T cells as a marker of the recent degranulation activity of HTLV-1-
specific CD8+ T cells in fresh PBMCs.  They observed a higher frequency of HTLV-1 peptide-
specific CD8+ T cells in patients with HAM/TSP than in asymptomatic HTLV-1 carriers.  
However, the frequency of CD107 staining was lower – indicating lower recent lytic activity – 
in specific CD8+ T cells from patients with HAM/TSP than in those from asymptomatic 
carriers.  The present results demonstrate the role of the CTL response in determining the 
proviral load of HTLV-1 infection both in patients with HAM/TSP and in healthy HTLV-1 
carriers.  Previous evidence from host immunogenetics (38) and analysis of the dynamics of 
the immune response to HTLV-1 (38) suggest that additional factors, as yet unidentified, cause 
the emergence of HAM/TSP in susceptible individuals. 
  
The results reported here suggest the following picture of chronic HTLV-1 infection. Efficient 
host control of HTLV-1 replication is associated with the presence of CD8+ T cells of high 
avidity, i.e. CD8+ T cells that respond to low antigen concentrations (low MHC/peptide density 
on the infected cell surface).  In a host with such an “efficient” CD8+ T cell response, an 
equilibrium is established between virus and host that is characterized by a low proviral load 
(1) and by high-avidity virus-specific CD8+ cells (4) (26) (14) that efficiently kill autologous 
HTLV-1-infected cells (Figure 3B).  Both the frequency and the per-cell intensity of HTLV-1 
antigen expression are low in such individuals (39) (Figure 1B and 5B).  The avidity of CD8+ 
T cell antigen recognition is likely to be determined by the host genotype, in particular the 
MHC class 1 genotype (3) (40) (38). 
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Figure legends 
 
Figure 1 Rate of lysis of HTLV-1-infected T cells by autologous CTLs is inversely 
correlated with the frequency of spontaneous proviral expression 
 
(A)  Rate of lysis of Tax+ cells by CTLs.  CD8+ cell-depleted PBMCs from a patient with 
HAM/TSP were incubated for 18h in the presence of increasing numbers of autologous CD8+ 
T cells.  The cells are gated on lymphocytes in 4 dot plots with progressively increasing 
numbers of CTLs. The figure in each quadrant denotes the percentage of CD4+ lymphocytes 
that express HTLV-1 Tax protein. The quadrant “normal” represents the normal frequency of 
CD8+ cells for that patient. 
 
(B)  Negative correlation between rate of CD8+-mediated lysis and proviral expression.  
Proviral expression and lytic efficiency (rate of lysis: see Materials and Methods) were assayed 
in a cohort of HTLV-infected patients (AC, ; HAM/TSP,).  The rate of spontaneous 
proviral expression in the absence of CTLs was quantified by incubating CD8+ cell-depleted 
PBMCs from HTLV-1-infected individuals in vitro for 18 hours. Tax protein expression by 
infected CD4+ T cells was detected by flow cytometry. P values were calculated using 
Spearman’s rank-sum test, and r2 values by linear regression of log-transformed data.   
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Figure 2 Determination of frequency and avidity of Tax-specific CD8+ T cells by IFN-γ 
ELISpot 
 
Repesentative data and curve-fitting for two HTLV-1 infected patients: one with high avidity 
CTL responses, and one with low avidity CTL responses.  CD4+ T cell-depleted PBMCs were 
incubated for 6 hours in the presence of a range of concentrations of two pools of peptides 
spanning the entire Tax protein, or in the presence of medium alone.  IFN-γ production by Tax-
specific cells was detected by ELISpot (A).   The frequency of Tax-specific T cells was 
calculated as follows. For each peptide concentration, the peptide-specific SFC was calculated 
by subtracting the mean SFC in no-peptide control wells from the SFC detected in the presence 
of peptide.  The peptide-specific SFC was then normalized to the total frequency of CD8+ T 
cells in the CD4+ cell-depleted PBMCs.  (B) To calculate the peptide concentration that gave 
half maximal SFC – the effective concentration at 50% (EC50), a sigmoidal curve (see 
Materials and Methods) was fitted to the experimental data (dashed line).  The predicted EC50 
is shown on the graph (solid line) with 95% confidence intervals (dotted lines) as calculated by 
the curve-fitting software.  The functional avidity of the HTLV-1-specific CD8+ T cells is 
defined as the reciprocal of the EC50. 
 
Figure 3 Rate of lysis of HTLV-1 infected CD4+ T cells is proportional to both the 
frequency and avidity of Tax-specific CD8+ T cells 
 
(A) Significant positive correlation between lytic efficiency and the frequency of Tax-specific 
CD8+ T cells measured in the IFN- ELISpot assay. 
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(B) Rate of lysis was also significantly correlated with the avidity (106M-1) of IFN-γ+ Tax- 
specific CD8+ T cells in a mixed cohort of HTLV-1-infected patients (AC, ; HAM/TSP,).  
P values were calculated using Spearman’s rank-sum test, and r2 values by linear regression of 
log-transformed data.   
  
Figure 4 CD8+ T-cell avidity is inversely correlated with proviral expression 
 
Negative correlation between IFN-γ+ CD8+ T cell avidity (106M-1) and spontaneous HTLV-1 
proviral expression by infected CD4+ cells in unfractionated PBMCs cultured for 18h.  P 
values were calculated using Spearman’s rank-sum test and r2 values by linear regression of 
log-transformed data.   
 
Figure 5: Taxhigh cells are killed more rapidly than Taxlow cells 
 
(A)   Tax expression by CD4+ T cells was detected by intracellular flow cytometry after 
incubation for 18h of CD8+ depleted or CD8+ enriched PBMC.  Dot plots are gated on 
CD4+Tax+lymphocytes. The Tax+ cells were divided into Taxlow and Taxhigh cells; the line 
dividing the two was arbitrarily defined, and the same definition was used throughout this 
study.  The results show a greater decrease in the frequency of Tax expression in the presence 
of enriched CD8+ cells. 
(B)   Negative correlation between the rate of lysis and the percentage of Taxhigh CD4+ cells in 
the Tax+ CD4+ gate (p<0.01; Spearman rank test, n=17). 
(C)   Rate of lysis of Taxhigh and Taxlow CD4+ cells was calculated using a modified version of 
our original mathematical model, which accounts for the transition of Tax+ cells from the 
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Taxlow to the Taxhigh gate.  Taxhigh cells were killed faster than Taxlow cells in the same 
individual (p<0.01; Mann Whitney, n=14). 
 





